ArticlePhysiological reports2026
Sex-specific hepatic effects of sweetened alcohol consumption and tannic acid intervention in adolescent rats.
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigated the combined effects of alcohol and sugar, termed sweetened alcohol consumption (SAC), and tannic acid (TA) intervention on hepatic health in adolescent rats. Sixty-four male and female 42-day-old Sprague-Dawley rats were assigned to control, TA (50 mg/kg), SAC (10% ethanol +20% fructose), or SAC+TA groups and treated for 10 weeks using a voluntary gelatine-based model. Growth parameters, feed intake, visceral fat, fasting glucose, insulin, HOMA-IR, lipid profiles, and hepatic outcomes, including mass, TBARS, gene expression, and histological features, were assessed. SAC reduced feed intake without affecting body mass. Females exposed to SAC showed increased visceral fat, elevated hepatic TBARS, reduced hepatocyte density, and more pronounced steatosis, indicating oxidative and structural susceptibility. In contrast, males exhibited increased HDL-cholesterol with reduced hepatic TBARS, suggesting sex-specific differences in hepatic metabolic adaptation. TA co-treatment prevented the SAC-associated increase in hepatic TBARS but did not preserve hepatocyte density or alter steatosis in females. Glucose homeostasis, insulin resistance, triglycerides, and hepatic expression of CYP2E1, SREBP-1, IL-10, NF-κB1, and TNF-α were unaffected across groups. Overall, SAC induces sex-dependent hepatic alterations during adolescence, with females showing heightened vulnerability. TA did not produce a measurable additional benefit when combined with SAC under the conditions used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.